Poujol S - Search Results

1

Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.

Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C, Bressolle F. Mougenot P, et al. Among authors: poujol s. Cancer Chemother Pharmacol. 2004 Jun;53(6):503-12. doi: 10.1007/s00280-003-0761-2. Epub 2004 Mar 9. Cancer Chemother Pharmacol. 2004. PMID: 15007638

2

Modeling plasma and saliva topotecan concentration time course using a population approach.

Boucaud M, Pinguet F, Culine S, Poujol S, Astre C, Gomeni R, Bressolle F. Boucaud M, et al. Among authors: poujol s. Oncol Res. 2003;13(4):211-9. Oncol Res. 2003. PMID: 12659422

3

Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.

Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, Pinguet F. Poujol S, et al. Cancer Chemother Pharmacol. 2006 Sep;58(3):292-305. doi: 10.1007/s00280-005-0166-5. Epub 2005 Dec 21. Cancer Chemother Pharmacol. 2006. PMID: 16369821 Clinical Trial.

4

In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.

Mougenot P, Bressolle F, Culine S, Solassol I, Poujol S, Pinguet F. Mougenot P, et al. Among authors: poujol s. Anticancer Res. 2006 May-Jun;26(3B):2197-203. Anticancer Res. 2006. PMID: 16821586 Free article. Clinical Trial.

5

Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

Boucaud M, Pinguet F, Poujol S, Romieu G, Cupissol D, Astre C, Culine S, Bressolle F. Boucaud M, et al. Among authors: poujol s. Eur J Cancer. 2001 Dec;37(18):2357-64. doi: 10.1016/s0959-8049(01)00312-4. Eur J Cancer. 2001. PMID: 11720828

6

Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.

Poujol S, Pinguet F, Malosse F, Astre C, Ychou M, Culine S, Bressolle F. Poujol S, et al. Clin Chem. 2003 Nov;49(11):1900-8. doi: 10.1373/clinchem.2003.023481. Clin Chem. 2003. PMID: 14578322 Clinical Trial.

7

Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.

Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, Pinguet F. Solassol I, et al. Among authors: poujol s. Ther Drug Monit. 2005 Aug;27(4):491-8. doi: 10.1097/01.ftd.0000160717.50704.42. Ther Drug Monit. 2005. PMID: 16044107 Clinical Trial.

8

Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.

Duffour J, Gourgou S, Desseigne F, Debrigode C, Mineur L, Pinguet F, Poujol S, Chalbos P, Bressole F, Ychou M. Duffour J, et al. Among authors: poujol s. Cancer Chemother Pharmacol. 2007 Aug;60(3):383-9. doi: 10.1007/s00280-006-0372-9. Epub 2006 Nov 24. Cancer Chemother Pharmacol. 2007. PMID: 17124595 Clinical Trial.

9

A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.

Poujol S, Pinguet F, Ychou M, Abderrahim AG, Duffour J, Bressolle FM. Poujol S, et al. Oncol Rep. 2007 Dec;18(6):1613-321. Oncol Rep. 2007. PMID: 17982652

10

High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study.

Gauvin A, Pinguet F, Poujol S, Astre C, Bressolle F. Gauvin A, et al. Among authors: poujol s. J Chromatogr B Biomed Sci Appl. 2000 Oct 10;748(2):389-99. doi: 10.1016/s0378-4347(00)00354-6. J Chromatogr B Biomed Sci Appl. 2000. PMID: 11087081

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page